<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7117595/results/search/disease/results.xml">
  <result pre="viable strategies to discover potential candidate drugs to combat severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)? Here we take a"/>
  <result pre="strategies to discover potential candidate drugs to combat severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)? Here we take a snapshot"/>
  <result pre="to discover potential candidate drugs to combat severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)? Here we take a snapshot look"/>
  <result pre="– that promises to identify antiviral agents for the novel" exact="coronavirus disease" post="in a time-critical fashion. We also offer a perspective"/>
  <result pre="that promises to identify antiviral agents for the novel coronavirus" exact="disease" post="in a time-critical fashion. We also offer a perspective"/>
  <result pre="agents [2]. Conceptually, BSAAs take advantage of the promiscuity of" exact="viral" post="replicative mechanisms and host interactions to target two or"/>
  <result pre="replicative mechanisms and host interactions to target two or more" exact="viral" post="families [3]. Following the COVID-19 outbreak in December 2019,"/>
  <result pre="II though IV. Umifenovir is a membrane fusion inhibitor targeting" exact="viral" post="entry and lopinavir/ritonavir is a drug combination targeting viral"/>
  <result pre="targeting viral entry and lopinavir/ritonavir is a drug combination targeting" exact="viral" post="protease, both approved for the indications of Influenza and"/>
  <result pre="in different combinations in a Phase IV clinical trial for" exact="pneumonia" post="associated with COVID-19 (ClinicalTrials.gov ID: NCT04255017) [4]. At the"/>
  <result pre="ID: NCT04255017) [4]. At the Phase III level, remdesivir, a" exact="viral" post="RNA-dependent RNA polymerase inhibitor, is under investigation for mild"/>
  <result pre="the species of coronaviridae implicated in SARS-CoV and Middle East" exact="respiratory" post="syndrome (MERS-CoV) [6]. Notably, it has already been studied"/>
  <result pre="species of coronaviridae implicated in SARS-CoV and Middle East respiratory" exact="syndrome" post="(MERS-CoV) [6]. Notably, it has already been studied in"/>
  <result pre="Other Phase III agents being evaluated in combination therapy for" exact="viral pneumonia" post="interestingly include the antimalarial hydroxychloroquine, based on promising in"/>
  <result pre="Phase III agents being evaluated in combination therapy for viral" exact="pneumonia" post="interestingly include the antimalarial hydroxychloroquine, based on promising in"/>
  <result pre="a synergizer of BSAAs [9]. At more early stages, the" exact="viral" post="RNA polymerase inhibitor favipiravir in combination is also on"/>
  <result pre="also on a Phase II clinical trial for novel coronavirus-associated" exact="pneumonia" post="(Chinese Clinical Trial Registry Identifier: ChiCTR2000029544) [10]. Finally, preclinical"/>
  <result pre="or more drugs acting on different cellular signaling pathways involving" exact="viral" post="replication with minimal redundancy. Another strategy is high-throughput screening"/>
  <result pre="combinations at the host–virus interactome level for emerging and re-emerging" exact="infectious diseases," post="which may allow researchers to narrow down the spectrum"/>
  <result pre="the drug development pipeline, lowering toxicity and minimizing emergence of" exact="secondary" post="resistance. Future perspective A notion that will determine the"/>
  <result pre="were to extrapolate the experience from precision oncology, where targeted" exact="cancer" post="therapies and immunotherapeutics have made major gains against cancer,"/>
  <result pre="sites with conserved residues causing conformational change of the entire" exact="viral" post="RNA repair complex. Therefore, the hunt should now be"/>
  <result pre="should now be on to identify an inhibitor of this" exact="viral" post="nuclease. Further, drug repurposing will have to compete with"/>
  <result pre="We can anticipate the notion of drug repurposing for emerging" exact="viral" post="diseases to be scrutinized based on these results. At"/>
  <result pre="prospective/retrospective,randomized controlled clinical study of antiviral therapy in the 2019-nCoV" exact="pneumonia" post="(2020). https://clinicaltrials.gov/ct2/show/NCT04255017 5.collab: NIH Clinical Trials. Mild/moderate 2019-nCoV remdesivir"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J. Biol. Chem.2020) (Epub ahead of print)."/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J. Biol. Chem.2020) (Epub ahead of print). 7.MulanguS"/>
  <result pre="DoffLE , DaveyRTJret al.A randomized, controlled trial of ebola virus" exact="disease" post="therapeutics. N. Engl. J. Med.381(24), 2293–2303 (2019).31774950 8.collab: NIH"/>
  <result pre="Clinical Trials. Efficacy and safety of hydroxychloroquine for treatment of" exact="pneumonia" post="caused by 2019-nCoV (HC-nCoV) (2020). https://clinicaltrials.gov/ct2/show/NCT04261517 9.WangM , CaoR"/>
  <result pre="efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel" exact="coronavirus pneumonia" post="(COVID-19) patients who are still positive on virus detection"/>
  <result pre="and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus" exact="pneumonia" post="(COVID-19) patients who are still positive on virus detection"/>
  <result pre="1189–1195 (2016).27240777 12.ChengYS , WilliamsonPR , ZhengWImproving therapy of severe" exact="infections" post="through drug repurposing of synergistic combinations. Curr. Opin. Pharmacol.48,"/>
  <result pre=", SunW , SimeonovADrug repurposing screens and synergistic drug-combinations for" exact="infectious diseases." post="Br. J. Pharmacol.175(2), 181–191 (2018).28685814 14.FerronF , SubissiL ,"/>
  <result pre="Rev.29(3), 695–747 (2016).27281742 20.MarstonHD , FolkersGK , MorensDM , FauciASEmerging" exact="viral" post="diseases: confronting threats with new technologies. Sci. Transl. Med.6(253),"/>
 </snippets>
</snippetsTree>
